ES2721001T3 - Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa - Google Patents
Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa Download PDFInfo
- Publication number
- ES2721001T3 ES2721001T3 ES15743281T ES15743281T ES2721001T3 ES 2721001 T3 ES2721001 T3 ES 2721001T3 ES 15743281 T ES15743281 T ES 15743281T ES 15743281 T ES15743281 T ES 15743281T ES 2721001 T3 ES2721001 T3 ES 2721001T3
- Authority
- ES
- Spain
- Prior art keywords
- treat
- compositions
- methods
- neurodegenerative disease
- isoindoline derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical class C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Abstract
Compuesto de fórmula:**Fórmula** o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461934528P | 2014-01-31 | 2014-01-31 | |
PCT/US2015/013754 WO2015116923A1 (en) | 2014-01-31 | 2015-01-30 | Isoindoline compositions and methods for treating neurodegenerative disease |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2721001T3 true ES2721001T3 (es) | 2019-07-26 |
Family
ID=53757753
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES15743281T Active ES2721001T3 (es) | 2014-01-31 | 2015-01-30 | Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa |
ES19154222T Active ES2915833T3 (es) | 2014-01-31 | 2015-01-30 | Composiciones de isoindolina y métodos para tratar una enfermedad neurodegenerativa y una degeneración macular |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES19154222T Active ES2915833T3 (es) | 2014-01-31 | 2015-01-30 | Composiciones de isoindolina y métodos para tratar una enfermedad neurodegenerativa y una degeneración macular |
Country Status (16)
Country | Link |
---|---|
US (5) | US9796672B2 (es) |
EP (3) | EP3498692B1 (es) |
JP (1) | JP6517827B2 (es) |
KR (1) | KR102331422B1 (es) |
CN (1) | CN106163516B (es) |
AU (1) | AU2015210852B2 (es) |
BR (1) | BR112016017808B1 (es) |
CA (1) | CA2938212C (es) |
DK (2) | DK3099296T3 (es) |
ES (2) | ES2721001T3 (es) |
HK (1) | HK1225651A1 (es) |
IL (1) | IL247003B (es) |
MX (1) | MX368755B (es) |
NZ (1) | NZ722599A (es) |
RU (1) | RU2692258C2 (es) |
WO (1) | WO2015116923A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA037918B1 (ru) | 2011-12-21 | 2021-06-07 | Новира Терапьютикс, Инк. | Противовирусные агенты против гепатита в |
UA123256C2 (uk) | 2012-08-28 | 2021-03-10 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Сульфамоїлариламіди та їх застосування як лікарських препаратів для лікування гепатиту b |
HUE034820T2 (en) | 2013-02-28 | 2018-02-28 | Janssen Sciences Ireland Uc | Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B |
ES2640063T3 (es) | 2013-04-03 | 2017-10-31 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
JP6348978B2 (ja) | 2013-07-25 | 2018-06-27 | ヤンセン・サイエンシズ・アイルランド・ユーシー | グリオキサミド置換ピロールアミド誘導体およびb型肝炎を処置するための医薬品としてのその使用 |
ES2655518T3 (es) | 2013-10-23 | 2018-02-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
BR112016017808B1 (pt) | 2014-01-31 | 2022-07-12 | Cognition Therapeutics, Inc | Composto ou sal farmaceuticamente aceitável, uso de um composto e composição para a inibição de um efeito betaamilóide numa célula neuronal |
KR20160128305A (ko) | 2014-02-05 | 2016-11-07 | 노비라 테라퓨틱스, 인코포레이티드 | Hbv 감염의 치료를 위한 병용 요법 |
CN110483484A (zh) | 2014-02-06 | 2019-11-22 | 爱尔兰詹森科学公司 | 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
US9884831B2 (en) | 2015-03-19 | 2018-02-06 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
EP3356328A1 (en) | 2015-09-29 | 2018-08-08 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
US11046670B2 (en) | 2015-10-19 | 2021-06-29 | Board Of Regents, The University Of Texas System | Piperazinyl norbenzomorphan compounds and methods for using the same |
KR20180129943A (ko) | 2016-04-15 | 2018-12-05 | 노비라 테라퓨틱스, 인코포레이티드 | 캡시드 조립 억제제를 포함하는 배합물 및 방법 |
EP3448520A4 (en) * | 2016-04-29 | 2020-07-29 | Board Of Regents, The University Of Texas System | SIGMA RECEIVER BINDERS |
CN107162944B (zh) * | 2017-04-27 | 2019-02-26 | 湖南化工研究院有限公司 | 2,3-二甲基苯甲硫醚的制备方法 |
KR102614814B1 (ko) * | 2017-05-15 | 2023-12-20 | 카그니션 테라퓨틱스, 인코퍼레이티드 | 신경변성 질환 치료용 조성물 |
EP3704092A4 (en) * | 2017-11-01 | 2021-08-25 | Cognition Therapeutics, Inc. | ISOINDOLINE COMPOSITIONS AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASE |
CA3090125A1 (en) | 2018-03-14 | 2019-09-19 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
JP6567153B1 (ja) * | 2018-09-28 | 2019-08-28 | 学校法人東北工業大学 | 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム |
CA3116348A1 (en) * | 2018-10-31 | 2020-05-07 | Polycore Therapeutics Llc | Method for synthesizing d3 dopamine receptor agonists |
CN113454077A (zh) | 2019-02-22 | 2021-09-28 | 爱尔兰詹森科学公司 | 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物 |
CN109734638A (zh) * | 2019-03-08 | 2019-05-10 | 新昌县大船畈生物科技有限公司 | 一种食用香精香料的制备方法 |
CN109734639B (zh) * | 2019-03-08 | 2020-10-09 | 漯河市卫龙生物技术有限公司 | 一种食用香精香料的制备方法 |
BR112021021454A2 (pt) | 2019-05-06 | 2021-12-21 | Janssen Sciences Ireland Unlimited Co | Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv |
CN112694427B (zh) * | 2019-10-23 | 2022-11-18 | 江西天宇化工有限公司 | 一种制备2,3-二甲基苯甲硫醚的方法 |
KR20220142477A (ko) * | 2020-02-13 | 2022-10-21 | 카그니션 테라퓨틱스, 인코퍼레이티드 | 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법 |
JP2023526515A (ja) | 2020-05-20 | 2023-06-21 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ | リソソーム蓄積症をヒスタチンペプチドで処置するための方法 |
KR20230118158A (ko) * | 2020-12-11 | 2023-08-10 | 카그니션 테라퓨틱스, 인코퍼레이티드 | 건성 노년기 황반 변성 (amd)을 치료하기 위한 조성물 |
WO2024020059A1 (en) * | 2022-07-18 | 2024-01-25 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
WO2024130030A1 (en) * | 2022-12-14 | 2024-06-20 | Fred Hutchinson Cancer Center | Method for treating neurological diseases through glial pruning regulation |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA732136B (en) | 1972-04-12 | 1974-03-27 | Lilly Co Eli | Dopamine derivatives |
DE2753278A1 (de) | 1977-11-30 | 1979-05-31 | Basf Ag | Aralkylpiperidinone |
US4321386A (en) | 1981-01-28 | 1982-03-23 | Mead Johnson & Company | Quaternary piperidinium halides |
DE3222152A1 (de) | 1982-06-12 | 1983-12-15 | Bayer Ag, 5090 Leverkusen | Substituierte maleinsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
GR79758B (es) | 1983-01-31 | 1984-10-31 | Lilly Co Eli | |
JPS62283922A (ja) | 1986-05-30 | 1987-12-09 | Tsumura Juntendo Inc | 血小板凝集抑制剤 |
US4697024A (en) | 1986-11-24 | 1987-09-29 | Merrell Dow Pharmaceuticals Inc. | Medroxalol intermediates |
US4958029A (en) * | 1987-01-13 | 1990-09-18 | Banyu Pharmaceutical Co., Ltd. | Process for the production of isoindoline derivatives, novel intermediates and process for their production |
JPH01180822A (ja) | 1988-01-12 | 1989-07-18 | Dainippon Pharmaceut Co Ltd | 抗遅延型アレルギー剤 |
JPH01305085A (ja) | 1988-05-31 | 1989-12-08 | Yamanouchi Pharmaceut Co Ltd | ピリジルチアゾリジンカルボン酸アミド誘導体 |
JPH02215789A (ja) | 1989-02-15 | 1990-08-28 | Yamanouchi Pharmaceut Co Ltd | チアゾロ[3,4―a]ピラジン誘導体 |
WO1991009594A1 (en) | 1989-12-28 | 1991-07-11 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
DE4000610A1 (de) | 1990-01-11 | 1991-07-18 | Knoll Ag | Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen |
JP2818958B2 (ja) | 1990-02-23 | 1998-10-30 | 塩野義製薬株式会社 | 4―(4―アルコキシフェニル)―2―ブチルアミン誘導体およびその製造法 |
JPH045266A (ja) | 1990-04-24 | 1992-01-09 | Toyo Pharma- Kk | ドパミン誘導体の製造方法 |
DE4142366A1 (de) | 1991-07-15 | 1993-06-24 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE69433714T2 (de) | 1991-08-23 | 2005-03-31 | NPS Pharmaceuticals, Inc., Salt Lake City | Kalzium - receptor aktive arylalkylamine |
US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
CA2115900A1 (en) | 1993-02-22 | 1994-08-23 | Gerald W. Becker | Pharmaceutical screens and antibodies |
JPH06321781A (ja) | 1993-05-13 | 1994-11-22 | Yamanouchi Pharmaceut Co Ltd | 血小板活性化因子拮抗剤 |
CZ290670B6 (cs) | 1994-10-21 | 2002-09-11 | Nps Pharmaceuticals, Inc. | Sloučeniny modulující receptory anorganických iontů a farmaceutický prostředek, který je obsahuje |
JP3522930B2 (ja) | 1995-12-06 | 2004-04-26 | 花王株式会社 | 抗菌剤及びこれを含有する口腔用組成物 |
EP0881220A4 (en) | 1996-02-15 | 1999-04-21 | Mitsubishi Chem Corp | DIARYLSULTAME DERIVATIVES |
CA2251625A1 (en) * | 1996-04-24 | 1997-10-30 | Yumiko Shibouta | Fused imidazopyridine derivatives as antihyperlipidemic agents |
US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
US6518315B1 (en) | 1997-10-21 | 2003-02-11 | The University Of Sydney | Medicinal uses of phenylaikanols and derivatives |
CO4980891A1 (es) | 1997-11-14 | 2000-11-27 | Sanofi Sa | Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer |
CO5011072A1 (es) | 1997-12-05 | 2001-02-28 | Lilly Co Eli | Etanolaminas pirazinil substituidas como agfonistas de los receptores |
IL138686A0 (en) | 1999-10-01 | 2001-10-31 | Pfizer Prod Inc | α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS |
WO2001030335A2 (en) | 1999-10-22 | 2001-05-03 | The Board Of Trustees Of The University Of Illinois | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
DE10027151A1 (de) | 2000-05-31 | 2001-12-06 | Bayer Ag | Herbizide Mittel auf Basis von substituierten Carbonsäureamiden |
CZ303572B6 (cs) | 2000-06-28 | 2012-12-12 | Smithkline Beecham P. L. C. | Jemne rozmelnený prostredek a zpusob jeho prípravy |
EP1481061B1 (en) | 2001-03-05 | 2011-06-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses |
JP4312402B2 (ja) | 2001-07-31 | 2009-08-12 | 有限会社大長企画 | 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤 |
AU2002332659A1 (en) | 2001-08-21 | 2003-03-03 | Sepracor, Inc. | 2-substituted piperidines that are ligands for monoamine receptors and transporters |
US6991814B2 (en) | 2001-12-13 | 2006-01-31 | Council Of Scientific And Industrial Research | Herbal medicaments for the treatment of neurocerebrovascular disorders |
EE05374B1 (et) | 2001-12-14 | 2011-02-15 | Council�of�Scientific�and�Industrial�Research | KompositsioonÁneurotserebrovaskulaarseteÁhireteÁravimiseksÁningÁmeetodÁsellesÁsisalduvaÁkurkumi?liÁvalmistamiseks |
JP2004002517A (ja) | 2002-05-31 | 2004-01-08 | Dae Sil Kim | 生姜成分を含む石鹸の組成物及びその製造方法 |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
DE10320560A1 (de) | 2003-05-07 | 2004-01-29 | Brosig, Stefan, Dr. | Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit |
US20050020483A1 (en) | 2003-06-12 | 2005-01-27 | Donna Oksenberg | Sigma ligands for neuronal regeneration and functional recovery |
US7829562B2 (en) | 2003-06-12 | 2010-11-09 | M's Science Corporation | Sigma ligands for neuronal regeneration and functional recovery |
BRPI0418634A (pt) | 2004-03-12 | 2007-05-29 | Egis Gyogyszergyar Nyrt | composição farmacêutica combinada para a inibição do declìnio das funções cognitivas |
CA2566202A1 (en) | 2004-05-31 | 2005-12-08 | Kaneka Corporation | Agent for preventing/ameliorating life style-related diseases containing turmeric essential oil component |
EP1794313B1 (en) | 2004-06-21 | 2013-05-15 | Proteome Sciences Plc | Screening methods using c-abl, fyn and syk in combination with tau protein |
TW200613272A (en) * | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
AU2005281783A1 (en) | 2004-09-10 | 2006-03-16 | Ucb Pharma, S.A. | Sigma receptor ligands |
US20080044356A1 (en) | 2004-10-22 | 2008-02-21 | Regents Of The University Of Minnesota | Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof |
US20060153772A1 (en) | 2004-12-15 | 2006-07-13 | Wyeth | Contextual fear conditioning for predicting immunotherapeutic efficacy |
AU2006222193B2 (en) | 2005-03-05 | 2011-11-17 | AbbVie Deutschland GmbH & Co. KG | Screening method, process for purifying of non-diffusible A-beta oligomers, selective antibodies against said non-diffusible A-beta oligomers and a process for manufacturing of said antibodies |
CA2611489A1 (en) | 2005-06-15 | 2006-12-28 | Darrick S.H.L. Kim | Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease including sage and rosemary derived compounds |
TW200726774A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Composition and method for producing stable amyloid beta oligomers |
EP1745778A3 (en) | 2005-07-20 | 2007-03-07 | Speedel Experimenta AG | Diaminoalcohols as therapeutic compounds |
ITRM20060007A1 (it) | 2006-01-05 | 2007-07-06 | Univ Bari | Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici |
US20070218491A1 (en) | 2006-02-08 | 2007-09-20 | Oligomerix, Inc. | Oligomerization of amyloid proteins |
MX2008011754A (es) | 2006-03-17 | 2008-09-30 | Herbalscience Singapore Pte Ltd | Extractos y metodos que comprenden especies de curcuma. |
WO2007112288A2 (en) | 2006-03-23 | 2007-10-04 | Mount Sinai School Of Medicine | Cardiovascular composition and use the same for the treatment of alzheimers disease |
WO2007126473A2 (en) | 2006-04-10 | 2007-11-08 | Oligomerix, Inc. | Oligomerization of amyloid proteins |
WO2008042024A2 (en) | 2006-06-01 | 2008-04-10 | Elan Pharmaceuticals, Inc. | Neuroactive fragments of app |
US7561775B2 (en) | 2006-08-22 | 2009-07-14 | Senko Advanced Components, Inc. | Fiber optic protective shutter |
EP2066692B1 (en) | 2006-09-08 | 2012-01-11 | VIB, vzw | Means and methods for the production of amyloid oligomers |
US7723377B2 (en) | 2006-09-29 | 2010-05-25 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
US20080131233A1 (en) | 2006-10-17 | 2008-06-05 | Yao Chun I | Plate-shaped fastener device |
US20100028333A1 (en) | 2006-12-15 | 2010-02-04 | Getty Krista L | Receptor for amyloid beta and uses thereof |
US20080171757A1 (en) | 2007-01-11 | 2008-07-17 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Serivces | Methods to identify inhibitors of cell sickling |
CA2719878C (en) | 2007-04-26 | 2017-08-29 | Yale University | Prion protein as a receptor for amyloid-beta oligomers |
MX2009012316A (es) | 2007-05-15 | 2009-12-03 | Helicon Therapeutics Inc | Metodos de tratamiento de trastornos cognitivos mediante la inhibicion de gpr12. |
CN101121670A (zh) | 2007-09-11 | 2008-02-13 | 上海紫源制药有限公司 | 一种3,4-二甲氧基-N-[3-(4-甲氧基苯基)-1-甲基-正丙基]-β-苯乙胺盐酸盐的制备方法 |
US20090246191A1 (en) | 2007-10-11 | 2009-10-01 | University Of Tennessee Research Foundation | Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof |
EP2206707B1 (en) | 2007-10-24 | 2014-07-23 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
US8168800B2 (en) | 2007-11-02 | 2012-05-01 | The Regents Of The University Of California | Aβ-binding small molecules |
US20110092554A1 (en) | 2007-11-19 | 2011-04-21 | Richard Chesworth | 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders |
CA2730804A1 (en) | 2008-07-25 | 2010-01-28 | Abbott Laboratories | Amyloid .beta. peptide analogues, oligomers thereof, processes for preparing and compositions comprising said analogues or oligomers, and their uses |
KR101515822B1 (ko) | 2008-11-29 | 2015-04-29 | 더 타일랜드 리서치 펀드 | 바이러스와 타겟 세포의 상호작용 저해 |
WO2010088450A2 (en) | 2009-01-30 | 2010-08-05 | Celladon Corporation | Methods for treating diseases associated with the modulation of serca |
DK2408905T3 (en) | 2009-03-16 | 2017-08-28 | Pangu Biopharma Ltd | Compositions and Methods comprising Histidyl-tRNA Synthetase Splicing Variants with Non-Canonical Biological Activities |
US7972164B2 (en) | 2009-03-24 | 2011-07-05 | Tyco Electronics Corporation | Connector assembly with a latch |
AU2010234518A1 (en) | 2009-04-09 | 2012-02-02 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
ES2581178T3 (es) | 2009-07-29 | 2016-09-01 | Pharnext | Nuevas herramientas de diagnóstico para enfermedad de Alzheimer |
JP2013501006A (ja) * | 2009-07-31 | 2013-01-10 | コグニション セラピューティクス インク. | 認知機能低下の阻害剤 |
US20150160228A1 (en) | 2010-02-05 | 2015-06-11 | Susan Catalano | Compositions and method for determining the efficacy of amyloidosis treatments |
WO2011106785A2 (en) | 2010-02-26 | 2011-09-01 | Cognition Therapeutics, Inc. | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith |
WO2012027548A1 (en) | 2010-08-25 | 2012-03-01 | The Feinstein Institute For Medical Research | Compounds and methods for prevention and treatment of alzheimer's and other diseases |
SG192596A1 (en) | 2011-02-02 | 2013-09-30 | Cognition Therapeutics Inc | Isolated compounds from turmeric oil and methods of use |
US20170049723A1 (en) | 2011-02-02 | 2017-02-23 | Cognition Therapeutics, Inc. | Isolated compounds from turmeric oil and methods of use |
WO2013029060A2 (en) | 2011-08-25 | 2013-02-28 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
BR112014004414A2 (pt) | 2011-08-25 | 2017-03-28 | Cognition Therapeutics Inc | composições e métodos para tratar doença neurodegenerativa |
AT511906B1 (de) | 2011-08-30 | 2016-05-15 | Blum Gmbh Julius | Schublade |
WO2015020523A1 (en) | 2013-08-07 | 2015-02-12 | Stichting Vu-Vumc | Biomarkers for early diagnosis of alzheimer's disease |
BR112016017808B1 (pt) | 2014-01-31 | 2022-07-12 | Cognition Therapeutics, Inc | Composto ou sal farmaceuticamente aceitável, uso de um composto e composição para a inibição de um efeito betaamilóide numa célula neuronal |
KR102614814B1 (ko) | 2017-05-15 | 2023-12-20 | 카그니션 테라퓨틱스, 인코퍼레이티드 | 신경변성 질환 치료용 조성물 |
EP3704092A4 (en) * | 2017-11-01 | 2021-08-25 | Cognition Therapeutics, Inc. | ISOINDOLINE COMPOSITIONS AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASE |
CN110283082A (zh) | 2019-07-15 | 2019-09-27 | 泰州职业技术学院 | 一种3-苯基丙胺的制备方法 |
KR20220142477A (ko) | 2020-02-13 | 2022-10-21 | 카그니션 테라퓨틱스, 인코퍼레이티드 | 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법 |
KR20230118158A (ko) | 2020-12-11 | 2023-08-10 | 카그니션 테라퓨틱스, 인코퍼레이티드 | 건성 노년기 황반 변성 (amd)을 치료하기 위한 조성물 |
-
2015
- 2015-01-30 BR BR112016017808-4A patent/BR112016017808B1/pt active IP Right Grant
- 2015-01-30 KR KR1020167023951A patent/KR102331422B1/ko active IP Right Grant
- 2015-01-30 CN CN201580017497.0A patent/CN106163516B/zh active Active
- 2015-01-30 ES ES15743281T patent/ES2721001T3/es active Active
- 2015-01-30 JP JP2016549224A patent/JP6517827B2/ja active Active
- 2015-01-30 NZ NZ722599A patent/NZ722599A/en unknown
- 2015-01-30 US US15/115,187 patent/US9796672B2/en active Active
- 2015-01-30 EP EP19154222.4A patent/EP3498692B1/en active Active
- 2015-01-30 RU RU2016134677A patent/RU2692258C2/ru active
- 2015-01-30 DK DK15743281.6T patent/DK3099296T3/en active
- 2015-01-30 ES ES19154222T patent/ES2915833T3/es active Active
- 2015-01-30 MX MX2016009845A patent/MX368755B/es active IP Right Grant
- 2015-01-30 CA CA2938212A patent/CA2938212C/en active Active
- 2015-01-30 AU AU2015210852A patent/AU2015210852B2/en active Active
- 2015-01-30 DK DK19154222.4T patent/DK3498692T3/da active
- 2015-01-30 EP EP15743281.6A patent/EP3099296B1/en active Active
- 2015-01-30 EP EP22155541.0A patent/EP4023294A1/en active Pending
- 2015-01-30 WO PCT/US2015/013754 patent/WO2015116923A1/en active Application Filing
-
2016
- 2016-07-28 IL IL247003A patent/IL247003B/en active IP Right Grant
- 2016-12-13 HK HK16114172A patent/HK1225651A1/zh unknown
-
2017
- 2017-09-11 US US15/700,923 patent/US10207991B2/en active Active
-
2018
- 2018-12-21 US US16/230,238 patent/US10611728B2/en active Active
-
2020
- 2020-02-06 US US16/783,943 patent/US11691947B2/en active Active
-
2023
- 2023-04-27 US US18/308,037 patent/US20240150288A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2721001T3 (es) | Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa | |
DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
SA519410025B1 (ar) | مثبطات ديميثيلاز-1 نوعي لللايسين | |
EA201691582A1 (ru) | Новые фармацевтические препараты | |
EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
EA201691940A1 (ru) | Новые соединения | |
EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
CL2016001458A1 (es) | Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo. | |
PE20151654A1 (es) | Inhibidores de cdc7 | |
CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
DOP2015000201A (es) | Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos | |
TN2015000519A1 (en) | Small molecule inhibitors of fibrosis | |
EA202090098A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
CL2016002940A1 (es) | Derivado de carotenoides, sal farmacéuticamente aceptable del mismo, o éster o amida farmacéuticamente aceptables del mismo | |
EP3169784A4 (en) | Organic compositions to treat apoc3-related diseases | |
CY1122264T1 (el) | Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων | |
EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
SV2017005381A (es) | Compuestos de imidazopiridazina | |
PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. | |
EA201791945A1 (ru) | Пирролидинкарбоксамидопроизводные и способы их получения и их применение | |
AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
EA201792264A1 (ru) | Способы лечения воспалительных заболеваний |